The big story today with Eli Lilly is its hugely successful GLP-1 drugs, but the long-term story is likely to be about its acquisitions.

The big story today with Eli Lilly is its hugely successful GLP-1 drugs, but the long-term story is likely to be about its acquisitions.

Eli Lilly (LLY) is back in focus after releasing 52 week data from its TOGETHER psoriasis and psoriatic arthritis trials, which tested Taltz with obesity drug Zepbound versus Taltz alone. Eli Lilly’s share price has eased recently, with a 7 day share price return of 2.15% and a 30 day share price return of 1.75%. However, the 1 year total shareholder return of 59.05% and the 5 year total shareholder return of about 5x suggest that momentum over longer periods remains strong. Capture Eli...

Superluminal Medicines has raised an oversubscribed $60 million Series B financing led by BVF Partners to advance its lead obesity program into clinical development and expand its AI-enabled drug discovery platform. New investors Deep Track Capital and Perceptive Advisors participated alongside existing investors RA Capital Management, Insight Partners, NVIDIA, Catalio Capital Management, Eli Lilly and Company, Cooley and Gaingels.

Eli Lilly (LLY) stock looks attractive vs. overextended semiconductors, with strong Q2 growth and reasonable PEG. See here for more details.

Eli Lilly and Company (NYSE:LLY) has launched Foundayo in the United Kingdom, making Britain the first European country where the company’s oral treatment for weight management and type 2 diabetes is available. The pill, known chemically as orforglipron, became available through private prescription after the UK medicines regulator authorised it on August 10. Its launch […]

Eli Lilly (NYSE:LLY) is in focus today as trades in a steadier healthcare session as the broad market rises, with sector conditions and company execution shaping the market narrative.

As part of the agreement with Upper Macungie, Eli Lilly officials agreed to follow a traffic study and continue to work with the township if future traffic issues arise.

The Upper Macungie Board of Supervisors granted final land development plan approval for Eli Lilly’s new manufacturing campus.

Eli Lilly returns to focus as healthcare themes, product activity, demand, competition, supply conditions, and broader markets evolve.

There is no end in sight for the company's incredible momentum.

BNP Paribas raised its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 4.4% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 38,251 shares of the company's stock after purchasing an additional 1,608 shares during the period. Eli Lilly and Company accounts for...